Salarius Pharmaceuticals Inc (SLRX) News

Salarius Pharmaceuticals Inc (SLRX): $2.03

-0.05 (-2.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SLRX News Items

SLRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SLRX News Highlights

  • SLRX's 30 day story count now stands at 2.
  • Over the past 7 days, the trend for SLRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • NOV and ASH are the most mentioned tickers in articles about SLRX.

Latest SLRX News From Around the Web

Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and nine months ended September 30, 2022 and provided a business update. Highlights of the third quarter of 2022 and recent weeks include: Financial Highlights Cash and cash equivalents were $16.8

Yahoo | November 10, 2022

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstracts related to the company’s compounds have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans and virtua

Yahoo | November 3, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of Hematology annual meeting later this year HOUSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today annou

Yahoo | October 27, 2022

Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference

HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiesteban

Yahoo | October 19, 2022

Akouos, AVEO lead healthcare gainers; Salarius, RVL among losers

Akouos AKUS +86%. AVEO Pharmaceuticals AVEO +40%. Salarius Pharmaceuticals (SLRX) -25%. RVL Pharmaceuticals (RVLP) -13%

Seeking Alpha | October 18, 2022

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that, as per protocol design, it is voluntarily pausing new patient enrollment in the company’s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas. The pause in new patient enrollment i

Yahoo | October 18, 2022

Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) stock: You might be surprised

Currently, Salarius Pharmaceuticals Inc.’s (SLRX) stock is trading at $0.19, marking a fall of -9.81% from last night’s close. At this price, the stock is -80.77% below its 52-week high of $0.99 and 18.45% above its 52-week low of $0.16. Based on the past 30-day period, the stock price is -33.98% below the high and […]

US Post News | October 14, 2022

Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) -9.13% Down Over A Week, Can The Stock Hit Well Above -$0.0340?

In recent trading session, Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) saw 1.34 million shares changing hands at last check today with its beta currently measuring 1.04. Company’s recent per share price level of $0.19 trading at -$0.02 or -9.81% at last check today assigns it a market valuation of $12.19M. That most recent trading price of SLRX’s … Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) -9.13% Down Over A Week, Can The Stock Hit Well Above -$0.0340? Read More »

Marketing Sentinel | October 14, 2022

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with the opening of trading on October 17, 2022, Salarius’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X

Yahoo | October 14, 2022

Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) Climbs 37.90% In 2022; Is It Attractive Enough At $0.19?

In last trading session, Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) saw 0.35 million shares changing hands with its beta currently measuring 1.03. Company’s recent per share price level of $0.19 trading at -$0.02 or -10.48% at ring of the bell on the day assigns it a market valuation of $10.00M. That closing price of SLRX’s stock is … Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) Climbs 37.90% In 2022; Is It Attractive Enough At $0.19? Read More »

Marketing Sentinel | September 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6078 seconds.